Cancer-seeking 'smart bombs' target kidney cancer cells
Research shows kidney cancer responds well to a developing immunotherapy that uses specialized antibodies to home in on renal cell carcinoma
2011-06-07
(Press-News.org) San Antonio, Texas (June 6, 2011)—Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy show dramatic slowing of cancer growth and stabilization of their disease.
"This study is another step forward in developing a cancer therapy that has the potential to provide additional treatment options for patients with renal cell carcinoma," says Wim Oyen, MD, professor and chairman of the department of nuclear medicine at Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. "In many cases we were able to stop the disease from progressing and hopefully prolong patient survival without compromising their quality of life with serious adverse effects."
According to the American Cancer Society, 50,000 Americans are diagnosed with kidney cancer each year. In adults, the most common type of kidney cancer is renal cell carcinoma.
Radioimmunotherapy is a treatment for cancer comprising medical radionuclides bound with antibodies that recognize physiological changes involved in the disease process. This specific therapy, called Lu-177-cG250, targets kidney tumors with the monoclonal antibody cG250, which recognizes carbonic anhydrase IX—an antigen associated with renal cell carcinoma. Once inside the body the treatment targets cancerous tissues expressing this antigen, and the radionuclide kills those cells, sparing surrounding healthy tissues.
For the purposes of this study, 20 patients with progressive, metastasized renal cell carcinoma received a maximum of three doses of Lu-177-cG250 and were evaluated for toxicity and therapeutic efficacy in three-month increments. A majority of patients, 14 out of 20, were able to reach stabilization of their cancer 12 weeks after treatment. Tumor growth averages dropped from 28.5 percent increase in size before treatment to 4.1 percent during the three months after their first treatment cycle. This study shows that Lu-177-cG250 is highly effective for targeting tumor lesions and for reducing cancer proliferation in patients with progressive kidney cancer.
INFORMATION:
Scientific Paper 359: A. Stillebroer, O. Boerman, P. Mulders, I. Desar, C. van Herpen, E. Oosterwijk, W. Oyen, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands; "Radioimmunotherapy with Lu-177 labeled anti-CAIX monoclonal antibody in advanced renal cell carcinoma," SNM's 58th Annual Meeting, June 4-8, 2011, San Antonio, TX.
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-06-07
San Antonio, Texas (June 6, 2011)—Research introduced at SNM's 58th Annual Meeting could be a sign of hope for patients with neuroendocrine cancer not responding well to standard therapies. Most radiotherapies use medical isotopes that emit beta radiation. The therapy in this study employs alpha particles, which have potential for higher potency. In fact, one single atom could be enough to kill an entire cancer cell.
"Until now, the usage of alpha radionuclides was limited to direct injection into the tumor or the use of only very small doses," says Clemens Kratochwil, ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Investigators at SNM's 58th Annual Meeting are presenting results from a phase 1 clinical trial for a cancer therapy that has the potential to kill colorectal tumors with less destruction of healthy tissue. Further research could lead to the use of this radioimmunotherapy to eliminate residual cancer after surgery or as a standard treatment to keep tumors from returning or spreading to other organs.
"Compared to the conventional way of guiding radiation to tumors with radiolabeled antibody, pretargeted radioimmunotherapy offers an attractive ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Research presented at SNM's 58th Annual Meeting is taking targeted molecular imaging to a new level by combining two commonly used imaging agents into one molecular imaging procedure. The combination of these agents creates a comprehensive examination of the extent of cancer spread within a variety of organ systems in the body.
"During a time when health care costs are under intense scrutiny, consolidated procedures such as this one that provide comprehensive imaging data are a benefit to everyone—to clinicians, healthcare administrators ...
2011-06-07
Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences (Early Edition, week of June 6), researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."
Spinal muscular atrophy, or SMA, affects one in every 1 in 6,000-10,000 infants, but an estimated ...
2011-06-07
San Antonio, Texas (June 6, 2011)—A study presented at SNM's 58th Annual Meeting may provide a new tool for detection of malignant-stage ovarian cancer. Researchers found that positron emission tomography and computed tomography (PET/CT), which images both functional and anatomical changes in the body, was useful for preoperative cancer imaging of ovarian masses when used with a radiotracer that is actively metabolized by cells as fuel. Physicians imaging patients suspected of having malignant tumors can see where cancerous cells are hyper-metabolizing the tracer and accurately ...
2011-06-07
San Antonio, Texas (June 6, 2011)—A study revealed at SNM's 58th Annual Meeting is comparing the breast-tumor detection capabilities of two very different imaging technologies—breast-specific gamma imaging (BSGI), which provides functional images of breast physiology, and ultrasound—for women with complex breast imaging cases that require further evaluation. Many women who have dense breast tissue (radiodense breasts) are difficult to image using mammography, currently the gold standard of breast imaging. For women whose mammograms are not clear enough to determine whether ...
2011-06-07
San Antonio, Texas (June 6, 2011)—Patients undergoing molecular imaging to evaluate their stomach's ability to clear food are going to have an altogether new kind of breakfast. A study presented at SNM's 58th Annual Meeting has confirmed that nuclear medicine technologists can effectively use oatmeal products radiolabeled with a medical isotope to target and image the emptying of the stomach.
"The current standard for molecular imaging of gastric emptying is radiolabeling egg meal, but there are patients who, either due to lifestyle choices or allergies, cannot eat eggs," ...
2011-06-07
(Boston) - Boston University School of Medicine (BUSM) researchers found that girls who followed the Dietary Approach to Stop Hypertension (DASH) diet pattern had a lower incidence of excess weight gain as measured by body mass index (BMI) over the 10-year period of their adolescence. These findings are reported in the Archives of Pediatrics & Adolescent Medicine.
Obesity is a major public health problem, with 17 percent of American children overweight and 67 percent of adults either overweight or obese. Excess weight during childhood leads to numerous health problems ...
2011-06-07
The implementation of virtual water into trading deals has been suggested as a realistic solution to solving the global inequality of renewable freshwater, but new research suggests that it may not be as revolutionary as first thought.
In a study published today, Tuesday 7 June, in IOP Publishing's journal Environmental Research Letters, researchers have claimed that virtual water is unlikely to increase water use equality, primarily because the existing amount of virtual water is not large enough to overcome the inequalities that exist.
Lead author David Seekell, ...
2011-06-07
Boston, Mass (June 6, 2011)—A new study finds that the cancer care provided by the Veterans Health Administration (VHA) for men 65 years and older is at least as good as, and by some measures better than, Medicare-funded fee-for-service care obtained through the private sector. The study, reported in the June 7 issue of Annals of Internal Medicine, was led by Nancy Keating, an associate professor of health care policy at Harvard Medical School.
Several factors could account for the high quality of VHA care. "Care in the VHA is much better coordinated than most other settings," ...
LAST 30 PRESS RELEASES:
[Press-News.org] Cancer-seeking 'smart bombs' target kidney cancer cells
Research shows kidney cancer responds well to a developing immunotherapy that uses specialized antibodies to home in on renal cell carcinoma
